for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up
Healthcare

BRIEF-AstraZeneca says U.S. FDA grants orphan drug status for potential eye drug

March 9 (Reuters) - AstraZeneca Plc :

* AstraZeneca’s potential medicine for neuromyelitis optica receives FDA orphan drug designation

* US FDA has granted orphan drug designation for investigational anti-cd19 monoclonal antibody, medi-551

* Developed by Medimmune, Medi-551 is currently in phase IIb clinical development for NMO Source text for Eikon: Further company coverage:

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up